文献速递消化系统肿瘤

肿瘤不可知循环肿瘤DNA分析改善结直肠癌肝转移切除术后复发监测:一项前瞻性队列研究

Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
PubMed 文献 · Eur J Cancer · 2022-01-22

该前瞻性队列研究纳入96例结直肠癌肝转移切除患者,连续采集499份血浆样本,用肿瘤不可知甲基化多重微滴数字PCR检测TriMeth分析循环肿瘤DNA。术后或辅助化疗后ctDNA阳性者无复发生存显著更差,连续检测可在影像学复发前检出ctDNA,CT不确定时ctDNA状态可预测复发。

要点

  • 术后或辅助化疗后ctDNA阳性者无复发生存显著低于ctDNA阴性者。
  • 连续TriMeth分析在55.6%的ctDNA阳性患者中于影像学复发前检出ctDNA,中位提前3.1个月。
  • CT扫描不确定时,ctDNA状态预测复发的阳性预测值为100%、阴性预测值为75%。

核心结论

  • 术后连续ctDNA分析具有强预后价值,且比标准结直肠癌肝转移监测工具对复发检测更敏感。
  • TriMeth为改善结直肠癌肝转移患者术后监测提供了多个机会。

研究设计与样本

  • 前瞻性队列研究,纳入96例接受结直肠癌肝转移切除术的患者。
  • 连续采集499份血浆样本,使用肿瘤不可知甲基化多重微滴数字PCR检测TriMeth进行分析。

主要发现

  • 术后ctDNA阳性患者无复发生存显著低于无ctDNA患者(HR 4.5,P < 0.0001)。
  • 辅助化疗后ctDNA阳性患者无复发生存显著低于无ctDNA患者(HR 8.4,P < 0.0001)。
  • ctDNA状态对复发的预测能力强于标准临床危险因素和癌胚抗原。
  • 连续TriMeth分析在55.6%的ctDNA阳性患者中于影像学复发前检出ctDNA,提前时间最长10.6个月(中位3.1个月)。
  • 监测期间24%的患者CT扫描不确定,与复发诊断显著延迟相关(中位3.5个月 vs 1.0个月,P < 0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nearly 50% of patients recur within two years after curatively intended resection of colorectal cancer liver metastasis (CRLM). The optimal surveillance strategy is unknown due to the lack of evidence. Here, we explored the potential for improving postoperative CRLM surveillance by performing serial circulating tumour DNA (ctDNA) assessments parallel to standard-of-care surveillance. EXPERIMENTAL DESIGN: 499 prospectively collected serial plasma samples from 96 patients undergoing CRLM resection were analysed using the tumour-agnostic methylation multiplex droplet-digital PCR test 'TriMeth'. RESULTS: Patients with ctDNA postoperatively or post adjuvant chemotherapy experienced a significant lower recurrence-free survival than patients without ctDNA (hazard ratio (HR) 4.5; P < 0.0001 and HR 8.4, P < 0.0001). ctDNA status was a stronger predictor of recurrence than standard clinical risk factors and carcinoembryonic antigen. Serial TriMeth analysis detected ctDNA before radiological recurrence in 55.6% of ctDNA-positive patients, with up to 10.6 months lead-time (median 3.1 months). During surveillance, 24% of patients had inconclusive CT scans, which was associated with a significant delay in recurrence diagnosis (median 3.5 months versus 1.0 month, P < 0.0001). Uniquely, ctDNA status at the time of inconclusive CT scans predicted recurrence with positive and negative predictive values of 100%, and 75% (P = 0.0003). Serial TriMeth analysis allowed ctDNA growth rate assessment and revealed that fast ctDNA growth was associated with poor overall survival (HR: 1.6, P = 0.0052). CONCLUSIONS: Serial postoperative ctDNA analysis has a strong prognostic value and is more sensitive for recurrence detection than standard-of-care CRLM surveillance tools. Altogether, TriMeth provides several opportunities for improving postoperative surveillance of CRLM patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Øgaard N, Reinert T, Henriksen TV, et al. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. Eur J Cancer. 2022. PMID: 35074652. doi:10.1016/j.ejca.2021.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。